This $146,500 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research at San Jose State University Research Foundation to explore how increased intracellular pH (pHi) regulates the proto-oncogene MYC and autophagy in cancer cells. The research aims to provide new insights into how pHi-regulated cellular behaviors enable tumorigenesis. Specifically, the project will identify...
This $380,337 federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will support research at the University of Washington to develop improved mRNA therapeutics for cancer treatment. The key objectives are to: Build predictive machine learning models that relate mRNA sequence to stability and translation, enabling the design of mRNA sequences with (a) high protein expression across cell types or (b) highly cell type-specific protein expression....
The National Cancer Institute (NCI) awarded a $1,217,906 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to Cosmyc Inc. in Dover, DE. The award, with a project period from June 2024 to May 2025, will support research aimed at understanding the fundamental biological mechanisms underlying cancer development, progression, and potential treatment interventions, with a focus on the inhibition of MYC:TRRAP interaction in cancer. The research is expected to...
The National Cancer Institute (NCI) has awarded a $244,048 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University. This 3-year grant, with a start date of September 1, 2024, supports research to identify functional effector domains within human RNA-binding proteins (RBPs) and investigate how dysregulation of RBP function can lead to cancer. The key objectives of this project are: 1) Use a high-throughput recruitment assay to evaluate the...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to investigate mechanisms underlying T-cell dysfunction within the tumor microenvironment. The $103,948 award will be used by the Sloan-Kettering Institute for Cancer Research to conduct two primary research aims: 1) Determine how local amino acid availability impacts the exhausted T-cell proteome and T-cell function, and 2) Examine...
The National Cancer Institute (NCI) awarded a $431,968 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Baylor College of Medicine. The grant, with a performance period from August 15, 2024 to July 31, 2029, will fund research to elucidate how the oncogenic MYCN gene drives metabolic reprogramming in high-risk neuroblastoma, leading to an immunosuppressive tumor microenvironment. The researchers aim to modulate the metabolic environment of neuroblastoma tumors to...
This $238,890 federal Project Grant award, issued by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research conducted by Duke University to explore the relationship between chromosomal instability, loss of chromosome 17p, and sensitivity to inhibition of the mitotic regulator NDE1 in cancer cells. The key objectives of the research are to define the relationship between NDE1 dependence, 17p loss, and chromosomal instability, characterize the...
The National Cancer Institute (NCI) awarded the University of Chicago a $377,870 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and validate highly stable and potent synthetic transcriptional repressors (STRs) that can directly target the oncogenic transcription factor MYC. The project aims to structurally and biochemically optimize the STRs, enhance their cellular and pharmacological delivery, and evaluate their efficacy in inhibiting MYC-driven cancer...
This $452,549 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by Emory University to comprehensively characterize the intrinsic molecular features and extrinsic tumor microenvironment of MYC-driven osteosarcoma. The key objectives are to: Identify the cross-species molecular signatures and cell-cell communications in MYC-hyperactivated human and murine osteosarcoma tumors. This will involve profiling intrinsic and...
The National Cancer Institute (NCI) awarded a $107,948 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Johns Hopkins University. The grant supports a comparative analysis of M-CSF and GM-CSF in human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. This research aims to advance the understanding of functional differences between M-CSF and GM-CSF induced tumor-associated macrophages (TAMs) and explore potential...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program provides $268,590 to The Johns Hopkins University to conduct research on the effects of MYC gene overexpression on protein translation dynamics and ribosome collisions in cancer cells. The key objectives are to investigate how MYC expression impacts protein synthesis, assess how it affects ribosome collision frequency and sensitivity to translation stress, and determine if translation stress increases apoptosis in cancers with high MYC levels. The research aims to provide novel insights into the link between MYC-driven increases in protein synthesis and the resulting translational stresses that may be exploited for new therapeutic strategies against MYC-driven cancers. The award period runs from September 2024 through March 2027.